VolitionRx Announces Reimbursement Submission for Nu.Q Cancer Assays in France.
ByAinvest
Friday, Jan 30, 2026 8:54 am ET1min read
VNRX--
VolitionRx Limited is preparing a reimbursement submission for its Nu.Q Cancer assays to French government agencies, supported by Hospices Civils de Lyon. The submission aims to introduce the test into routine clinical practice in France for lung cancer management later this year. The test measures methylated nucleosome biomarker levels to enhance treatment selection and monitoring. Reimbursement is a major milestone for Volition in the commercialization and licensing of Nu.Q in the human cancer field.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet